Compare MNY & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNY | LUNG |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.7M | 63.6M |
| IPO Year | N/A | 2020 |
| Metric | MNY | LUNG |
|---|---|---|
| Price | $1.32 | $1.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $4.00 | ★ $6.81 |
| AVG Volume (30 Days) | 62.4K | ★ 1.1M |
| Earning Date | 12-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $68,998,322.00 | ★ $91,664,000.00 |
| Revenue This Year | $15.76 | $9.21 |
| Revenue Next Year | $20.60 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 15.59 |
| 52 Week Low | $0.55 | $1.31 |
| 52 Week High | $2.40 | $9.37 |
| Indicator | MNY | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 49.05 | 55.23 |
| Support Level | $1.28 | $1.57 |
| Resistance Level | $1.37 | $1.86 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 44.44 | 71.64 |
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services. Geographically it operates in Singapore, Hong Kong, Taiwan, Malaysia and the Philippines.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.